nach oben

Erschienen in:

01.08.2014 | Review Article

Osteoporosis and Multiple Sclerosis: Risk Factors, Pathophysiology, and Therapeutic Interventions

verfasst von: Sahil Gupta, Irfan Ahsan, Naeem Mahfooz, Noureldin Abdelhamid, Murali Ramanathan, Bianca Weinstock-Guttman

Erschienen in: CNS Drugs | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

Multiple sclerosis (MS) is a chronic inflammatory-demyelinating disease of the nervous system. There has been mounting evidence showing that MS is associated with increased risk of osteoporosis and fractures. The development of osteoporosis in MS patients can be related to the cumulative effects of various factors. This review summarizes the common risk factors and physiologic pathways that play a role in development of osteoporosis in MS patients. Physical inactivity and reduced mechanical load on the bones (offsetting gravity) is likely the major contributing factor for osteoporosis in MS. Additional possible factors leading to reduced bone mass are low vitamin D levels, and use of medications such as glucocorticoids and anticonvulsants. The role of the inflammatory processes related to the underlying disease is considered in the context of the complex bone metabolism. The known effect of different MS disease-modifying therapies on bone health is limited. An algorithm for diagnosis and management of osteoporosis in MS is proposed.

Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502–17.PubMedCrossRef

Sa MJ. Physiopathology of symptoms and signs in multiple sclerosis. Arq Neuropsiquiatr. 2012;70(9):733–40.PubMedCrossRef

Weinstock-Guttman B, et al. Risk of bone loss in men with multiple sclerosis. Mult Scler. 2004;10(2):170–5.PubMedCrossRef

Hearn AP, Silber E. Osteoporosis in multiple sclerosis. Mult Scler. 2010;16(9):1031–43.PubMedCrossRef

Zorzon M, et al. Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis. Eur J Neurol. 2005;12(7):550–6.PubMedCrossRef

Marrie RA, et al. A cross-sectional study of bone health in multiple sclerosis. Neurology. 2009;73(17):1394–8.PubMedCentralPubMedCrossRef

Sioka C, Kyritsis AP, Fotopoulos A. Multiple sclerosis, osteoporosis, and vitamin D. J Neurol Sci. 2009;287(1–2):1–6.PubMedCrossRef

Gibson JC, Summers GD. Bone health in multiple sclerosis. Osteoporos Int. 2011;22(12):2935–49.PubMedCrossRef

Josyula S, et al. The nervous system’s potential role in multiple sclerosis associated bone loss. J Neurol Sci. 2012;319(1–2):8–14.PubMedCrossRef

10.

Ye S, Wu R, Wu J. Multiple sclerosis and fracture. Int J Neurosci. 2013;123(9):609–16.PubMedCrossRef

11.

Levis S, Theodore G. Summary of AHRQ’s comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report. J Manag Care Pharm. 2012;18(4 Suppl B):S1–15 (discussion S13).PubMed

12.

Cosman F, et al. Fracture history and bone loss in patients with MS. Neurology. 1998;51(4):1161–5.PubMedCrossRef

13.

Nieves J, et al. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology. 1994;44(9):1687–92.PubMedCrossRef

14.

Ozgocmen S, et al. Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity. J Bone Miner Metab. 2005;23(4):309–13.PubMedCrossRef

15.

Achiron A, et al. Bone strength in multiple sclerosis: cortical midtibial speed-of-sound assessment. Mult Scler. 2004;10(5):488–93.PubMedCrossRef

16.

Moen SM, et al. Low bone mass in newly diagnosed multiple sclerosis and clinically isolated syndrome. Neurology. 2011;77(2):151–7.PubMedCrossRef

17.

Heaney RP. Pathophysiology of osteoporosis. Endocrinol Metab Clin North Am. 1998;27(2):255–65.PubMedCrossRef

18.

Sipos W, et al. Pathophysiology of osteoporosis. Wien Med Wochenschr. 2009;159(9–10):230–4.PubMedCrossRef

19.

Luis Neyro J, Jesus Cancelo M, Palacios S. Inhibition of RANK-L in the pathophysiology of osteoporosis. Clinical evidences of its use. Ginecol Obstet Mex. 2013;81(3):146–57.PubMed

20.

Negishi-Koga T, et al. Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med. 2011;17(11):1473–80.PubMedCrossRef

21.

Korn T. Pathophysiology of multiple sclerosis. J Neurol. 2008;255(Suppl 6):2–6.PubMedCrossRef

22.

Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med. 1995;332(5):305–11.PubMedCrossRef

23.

McLean RR. Proinflammatory cytokines and osteoporosis. Curr Osteoporos Rep. 2009;7(4):134–9.PubMedCrossRef

24.

Altintas A, et al. The role of osteopontin: a shared pathway in the pathogenesis of multiple sclerosis and osteoporosis? J Neurol Sci. 2009;276(1–2):41–4.PubMedCrossRef

25.

Vogt MH, et al. Increased osteopontin plasma levels in multiple sclerosis patients correlate with bone-specific markers. Mult Scler. 2010;16(4):443–9.PubMedCrossRef

26.

Slavov GS, et al. Vitamin D immunomodulatory potential in multiple sclerosis. Folia Med (Plovdiv). 2013;55(2):5–9.

27.

Munger KL, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology. 2004;62(1):60–5.PubMedCrossRef

28.

George PM, et al. Pharmacology and therapeutic potential of interferons. Pharmacol Ther. 2012;135(1):44–53.PubMedCrossRef

29.

Abraham AK, et al. Mechanisms of interferon-beta effects on bone homeostasis. Biochem Pharmacol. 2009;77(12):1757–62.PubMedCrossRef

30.

Moen SM, et al. Bone turnover and metabolism in patients with early multiple sclerosis and prevalent bone mass deficit: a population-based case-control study. PLoS One. 2012;7(9):e45703.PubMedCentralPubMedCrossRef

31.

Thomas T, et al. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology. 1999;140(4):1630–8.PubMed

32.

Gordeladze JO, et al. Leptin stimulates human osteoblastic cell proliferation, de novo collagen synthesis, and mineralization: impact on differentiation markers, apoptosis, and osteoclastic signaling. J Cell Biochem. 2002;85(4):825–36.PubMedCrossRef

33.

Ducy P, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell. 2000;100(2):197–207.PubMedCrossRef

34.

Elefteriou F, et al. Serum leptin level is a regulator of bone mass. Proc Natl Acad Sci USA. 2004;101(9):3258–63.PubMedCentralPubMedCrossRef

35.

Ruhl CE, et al. Body mass index and serum leptin concentration independently estimate percentage body fat in older adults. Am J Clin Nutr. 2007;85(4):1121–6.PubMed

36.

Friedman JM. The function of leptin in nutrition, weight, and physiology. Nutr Rev. 2002;60(10 Pt 2):S1–14 (discussion S68–84, 85–7).PubMedCrossRef

37.

Glauber HS, et al. Body weight versus body fat distribution, adiposity, and frame size as predictors of bone density. J Clin Endocrinol Metab. 1995;80(4):1118–23.PubMed

38.

Wardlaw GM. Putting body weight and osteoporosis into perspective. Am J Clin Nutr. 1996;63(3 Suppl):433S–6S.PubMed

39.

Carlton ED, Demas GE, French SS. Leptin, a neuroendocrine mediator of immune responses, inflammation, and sickness behaviors. Horm Behav. 2012;62(3):272–9.PubMedCrossRef

40.

Yadav VK, et al. A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell. 2009;138(5):976–89.PubMedCentralPubMedCrossRef

41.

Veniant MM, LeBel CP. Leptin: from animals to humans. Curr Pharm Des. 2003;9(10):811–8.PubMedCrossRef

42.

De Rosa V, et al. Leptin neutralization interferes with pathogenic T cell autoreactivity in autoimmune encephalomyelitis. J Clin Invest. 2006;116(2):447–55.PubMedCentralPubMedCrossRef

43.

Matarese G, et al. Requirement for leptin in the induction and progression of autoimmune encephalomyelitis. J Immunol. 2001;166(10):5909–16.PubMedCrossRef

44.

Budhiraja S, Chugh A. Neuromedin U: physiology, pharmacology and therapeutic potential. Fund Clin Pharmacol. 2009;23(2):149–57.CrossRef

45.

Sato S, et al. Central control of bone remodeling by neuromedin U. Nat Med. 2007;13(10):1234–40.PubMedCrossRef

46.

Shi YC, Baldock PA. Central and peripheral mechanisms of the NPY system in the regulation of bone and adipose tissue. Bone. 2012;50(2):430–6.PubMedCrossRef

47.

Khor EC, Baldock P. The NPY system and its neural and neuroendocrine regulation of bone. Curr Osteoporos Rep. 2012;10(2):160–8.PubMedCrossRef

48.

Inose H, et al. Efficacy of serotonin inhibition in mouse models of bone loss. J Bone Miner Res. 2011;26(9):2002–11.PubMedCrossRef

49.

Karsenty G, Yadav VK. Regulation of bone mass by serotonin: molecular biology and therapeutic implications. Annu Rev Med. 2011;62:323–31.PubMedCrossRef

50.

Yuan XQ, et al. Fluoxetine promotes remission in acute experimental autoimmune encephalomyelitis in rats. Neuroimmunomodulation. 2012;19(4):201–8.PubMedCrossRef

51.

Elefteriou F, et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature. 2005;434(7032):514–20.PubMedCrossRef

52.

Shi Y, et al. Signaling through the M(3) muscarinic receptor favors bone mass accrual by decreasing sympathetic activity. Cell Metab. 2010;11(3):231–8.PubMedCentralPubMedCrossRef

53.

Smith CJ, Fischer TH. Particulate and vapor phase constituents of cigarette mainstream smoke and risk of myocardial infarction. Atherosclerosis. 2001;158(2):257–67.PubMedCrossRef

54.

Didilescu AC, et al. The role of smoking in changing essential parameters in body homeostasis. Pneumologia. 2009;58(2):89–94.PubMed

55.

Emre M, de Decker C. Effects of cigarette smoking on motor functions in patients with multiple sclerosis. Arch Neurol. 1992;49(12):1243–7.PubMedCrossRef

56.

Zivadinov R, et al. Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis. Neurology. 2009;73(7):504–10.PubMedCentralPubMedCrossRef

57.

Manouchehrinia A, et al. Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study. Brain. 2013;136(Pt 7):2298–304.PubMedCentralPubMedCrossRef

58.

Hernan MA, Olek MJ, Ascherio A. Cigarette smoking and incidence of multiple sclerosis. Am J Epidemiol. 2001;154(1):69–74.PubMedCrossRef

59.

Brot C, Jorgensen NR, Sorensen OH. The influence of smoking on vitamin D status and calcium metabolism. Eur J Clin Nutr. 1999;53(12):920–6.PubMedCrossRef

60.

Fini M, et al. Role of obesity, alcohol and smoking on bone health. Front Biosci (Elite Ed). 2012;4:2686–706.CrossRef

61.

Borer KT. Physical activity in the prevention and amelioration of osteoporosis in women: interaction of mechanical, hormonal and dietary factors. Sports Med. 2005;35(9):779–830.PubMedCrossRef

62.

Mojtahedi MC, et al. Bone health in ambulatory individuals with multiple sclerosis: impact of physical activity, glucocorticoid use, and body composition. J Rehabil Res Dev. 2008;45(6):851–61.PubMedCrossRef

63.

Steffensen LH, Mellgren SI, Kampman MT. Predictors and prevalence of low bone mineral density in fully ambulatory persons with multiple sclerosis. J Neurol. 2010;257(3):410–8.PubMedCrossRef

64.

De Nijs RN. Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options. Minerva Med. 2008;99(1):23–43.PubMed

65.

Dovio A, et al. Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. J Clin Endocrinol Metab. 2004;89(10):4923–8.PubMedCrossRef

66.

Tuzun S, et al. Bone status in multiple sclerosis: beyond corticosteroids. Mult Scler. 2003;9(6):600–4.PubMedCrossRef

67.

Schwid SR, et al. Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis. Arch Neurol. 1996;53(8):753–7.PubMedCrossRef

68.

Olafsson E, Benedikz J, Hauser WA. Risk of epilepsy in patients with multiple sclerosis: a population-based study in Iceland. Epilepsia. 1999;40(6):745–7.PubMedCrossRef

69.

Ghezzi A, et al. Epilepsy in multiple sclerosis. Eur Neurol. 1990;30(4):218–23.PubMedCrossRef

70.

Petty SJ, et al. Effect of antiepileptic medication on bone mineral measures. Neurology. 2005;65(9):1358–65.PubMedCrossRef

71.

Lee RH, Lyles KW, Colon-Emeric C. A review of the effect of anticonvulsant medications on bone mineral density and fracture risk. Am J Geriatr Pharmacother. 2010;8(1):34–46.PubMedCentralPubMedCrossRef

72.

Truini A, et al. A mechanism-based classification of pain in multiple sclerosis. J Neurol. 2013;260(2):351–67.PubMedCentralPubMedCrossRef

73.

Solaro C, Trabucco E, Messmer Uccelli M. Pain and multiple sclerosis: pathophysiology and treatment. Curr Neurol Neurosci Rep. 2013;13(1):320.PubMedCrossRef

74.

Daniell HW. OPioid osteoporosis. Arch Internal Med. 2004;164(3):338.CrossRef

75.

Elhassan AM, et al. Methionine-enkephalin in bone and joint tissues. J Bone Miner Res. 1998;13(1):88–95.PubMedCrossRef

76.

Loskutova N, et al. Bone density and brain atrophy in early Alzheimer’s disease. J Alzheimers Dis. 2009;18(4):777–85.PubMedCentralPubMed

77.

Batista S, et al. Cognitive impairment is associated with reduced bone mass in multiple sclerosis. Mult Scler. 2012;18(10):1459–65.PubMedCrossRef

78.

Shuhaibar M, et al. Favorable effect of immunomodulator therapy on bone mineral density in multiple sclerosis. Ir J Med Sci. 2009;178(1):43–5.PubMedCrossRef

79.

Weinstock-Guttman B, et al. Interferon-beta modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients. Mult Scler. 2006;12(5):541–50.PubMedCrossRef

80.

National Osteoporosis Foundation. NOF’s clinicians’ guide to the prevention and treatment of osteoporosis (http://nof.org/hcp/resources/913.

81.

Ishii M, et al. Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature. 2009;458(7237):524–8.PubMedCentralPubMedCrossRef

82.

Sato C, et al. Sphingosine 1-phosphate receptor activation enhances BMP-2-induced osteoblast differentiation. Biochem Biophys Res Commun. 2012;423(1):200–5.PubMedCrossRef

83.

Huang C, et al. Local delivery of FTY720 accelerates cranial allograft incorporation and bone formation. Cell Tissue Res. 2012;347(3):553–66.PubMedCentralPubMedCrossRef

84.

Kanis JA, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385–97.PubMedCentralPubMedCrossRef

85.

Melton LJ 3rd, et al. Potential extensions of the US FRAX algorithm. J Osteoporos. 2012;2012:528790.PubMedCentralPubMedCrossRef

86.

Dennison EM, et al. Effect of co-morbidities on fracture risk: findings from the global longitudinal study of osteoporosis in women (GLOW). Bone. 2012;50(6):1288–93.PubMedCrossRef

87.

Bazelier MT, et al. A simple score for estimating the long-term risk of fracture in patients with multiple sclerosis. Neurology. 2012;79(9):922–8.PubMedCentralPubMedCrossRef

88.

Sundstrom P, Salzer J. Vitamin D and multiple sclerosis: timing of sampling, treatment and prevention. Biomark Med. 2013;7(2):193–5.PubMedCrossRef

89.

Myhr KM. Vitamin D treatment in multiple sclerosis. J Neurol Sci. 2009;286(1–2):104–8.PubMedCrossRef

90.

Weinstock-Guttman B, et al. Vitamin D and multiple sclerosis. Neurologist. 2012;18(4):179–83.PubMedCrossRef

91.

Ascherio A, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol. 2014;71(3):306–14.PubMedCrossRef

92.

Kmietowicz Z. NICE publishes osteoporosis guidance after more than six years of consultation. BMJ. 2008;337:a2397.PubMedCrossRef

93.

Compston J. NICE: its influence in treating osteoporosis in the UK and beyond. Ther Adv Musculoskelet Dis. 2009;1(2):63–6.PubMedCentralPubMedCrossRef

94.

McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014; 370(5):412-20

95.

Cummings SR, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med. 2010;362(8):686–96.PubMedCrossRef

96.

Trojano M, et al. The transition from relapsing-remitting MS to irreversible disability: clinical evaluation. Neurol Sci. 2003;24(Suppl 5):S268–70.PubMedCrossRef

97.

Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med. 2008;358(12):1304–6.PubMedCrossRef

98.

Black DM, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010;362(19):1761–71.PubMedCrossRef

99.

Odvina CV, et al. Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol. 2010;72(2):161–8.CrossRef

100.

Shane E, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American society for bone and mineral research. J Bone Miner Res. 2014;29(1):1–23.PubMedCrossRef

101.

Formica CA, et al. Reduced bone mass and fat-free mass in women with multiple sclerosis: effects of ambulatory status and glucocorticoid use. Calcif Tissue Int. 1997;61(2):129–33.PubMedCrossRef

Titel: Osteoporosis and Multiple Sclerosis: Risk Factors, Pathophysiology, and Therapeutic Interventions
verfasst von: Sahil Gupta
Irfan Ahsan
Naeem Mahfooz
Noureldin Abdelhamid
Murali Ramanathan
Bianca Weinstock-Guttman
Publikationsdatum: 01.08.2014
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 8/2014
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.1007/s40263-014-0173-3

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Demenz Nachrichten

Der Einsatz von Antipsychotika gegen psychische und Verhaltenssymptome in Zusammenhang mit Demenzerkrankungen erfordert eine sorgfältige Nutzen-Risiken-Abwägung. Neuen Erkenntnissen zufolge sind auf der Risikoseite weitere schwerwiegende Ereignisse zu berücksichtigen.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2014

Diclofenac Potassium Powder for Oral Solution: A Review of Its Use in Patients with Acute Migraine

Sodium Oxybate in the Treatment of Alcohol Withdrawal Syndrome: A Randomized Double-Blind Comparative Study versus Oxazepam. The GATE 1 Trial

Sociodemographic Disparities in Administration of Antiepileptic Drugs to Adults with Epilepsy in Germany: A Retrospective, Database Study of Drug Prescriptions

Perispinal Etanercept for Post-Stroke Neurological and Cognitive Dysfunction: Scientific Rationale and Current Evidence

Orexin/Hypocretin Based Pharmacotherapies for the Treatment of Addiction: DORA or SORA?